Biologics in spine arthrodesis.

Area of Science:

• Orthopedic Surgery
• Biomaterials Science
• Regenerative Medicine

Background:

• Spine fusion is vital for treating trauma, tumors, and degenerative conditions.
• Fusion failure necessitates exploring advanced spinal biologics for cellular-level impact.
• Historically, autograft was standard, but complications drive the search for alternatives.

Purpose of the Study:

• To review current bone graft options for spinal arthrodesis.
• To discuss the advantages and disadvantages of various spinal biologics.
• To highlight emerging trends like nanotechnology in spinal fusion.

Main Methods:

• Literature review of spinal fusion biologics.
• Analysis of osteogenic, osteoinductive, and osteoconductive properties.
• Evaluation of safety and efficacy data for bone graft substitutes.

Main Results:

• Current options include autograft, allograft, demineralized bone matrix, ceramics, stem cells, and recombinant human bone morphogenetic protein (Rh-BMP2).
• Rh-BMP2 use is associated with off-label concerns and adverse effects.
• Nanotechnology shows promise for binding endogenous growth factors, potentially mitigating risks.

Conclusions:

• Bone graft selection is critical for successful spinal fusion and patient outcomes.
• Orthopaedic surgeons need education on the utility and limitations of spinal biologics.
• Ongoing research focuses on safer and more effective spinal fusion materials.